NR1H4 and metabolic dysfunction-associated steatohepatitis: FXR has emerged as an attractive target for drug development in the treatment of liver diseases, and over 10 FXR agonists have entered clinical phase II/III clinical development to evaluate their effects on PBC and NASH (Gioiello et al., 2024).